ClinicalTrials.gg
RecruitingNCT04038619Updated Sep 18, 2026

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

A Phase 1 interventional study of Fecal Microbiota Transplantation and Loperamide in Colitis, Diarrhea and Malignant Genitourinary System Neoplasm, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by M.D. Anderson Cancer Center · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2021; still recruiting 5 years 9 months later.
Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This trial studies how well fecal microbiota transplantation works in treating diarrhea or colitis (inflammation of the intestines) that is caused by certain types of medications (called immune-checkpoint inhibitors) in patients with genitourinary cancer. Fecal microbiota transplantation may effectively reduce the incidence of immune checkpoint inhibitor-induced diarrhea/colitis.

Read the detailed description

PRIMARY OBJECTIVES:

  • To assess the safety and tolerability of fecal microbiota transplantation (FMT).
  • To assess the efficacy of FMT for clinical remission/response of immune-related diarrhea/colitis.

SECONDARY OBJECTIVES:

- To measure the recurrence rate after achieving clinical remission/response of immune-related diarrhea/colitis.

EXPLORATORY OBJECTIVES:

  • To assess the efficacy of FMT to achieve endoscopic remission of immune-related diarrhea/colitis.
  • To assess the efficacy of FMT to achieve histological remission of immune-related diarrhea/colitis.
  • To assess the efficacy of FMT on recurrence of immune-related diarrhea/colitis after resumption of immune checkpoint inhibitors (ICPI).
  • To assess immunological, molecular and microbiome changes in tissue/blood/stool.

To study the efficacy and/ or benefit of PuraStat gel in the healing of mucosal ulcers and its hemostatic effect on bleeding lesions

OUTLINE:

Patients receive loperamide orally (PO). After 4 hours, patients undergo FMT via colonoscopy over 15-30 minutes.

After completion of study treatment, patients are followed up at 2, 4, and 8 weeks, and then at 3 months.

02

Conditions studied

  • Colitis
  • Diarrhea
  • Malignant Genitourinary System Neoplasm
  • Melanoma
  • Lung Cancer
  • Ovarian Cancer
  • Uterine Cancer
  • Breast Cancer
  • Cervical Cancer
03

In context

Colitis

127 studies on the registry are indexed under Colitis; 31 are open to participants now.

This study's planned enrollment of 40 is below the median of 66 across 91 interventional studies indexed under Colitis.

Browse Colitis studies →

Lead sponsor

M.D. Anderson Cancer Center is the lead sponsor of 3,047 studies on the registry; 578 are open to participants now.

Of its 612 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of any type of genitourinary (kidney, bladder and prostate), melanoma, non-melanoma skin cancer, lung, head \& neck, sarcoma/lymphoma, gastrointestinal system (luminal GI, hepatobiliary, pancreas), gynecology system (ovarian, uterine, cervical), and breast
  2. Treatment with any ICPI agent(s)
  3. Participants with new onset of ≥ grade 2 ICPI-induced diarrhea and/or colitis symptoms based on the (CTCAE) version 5 within 45 days prior to date of FMT treatment without involvement of non- GI toxicity
  4. Participants with a history of use before FMT can be allowed if last dose was > 30 days prior to FMT treatment or treatment duration was for \<7 days beyond one week prior to FMT treatment
  5. Participants with a history of (Infliximab, Vedolizumab etc) use before FMT can be allowed if last dose was administered ≥ 3 months prior to FMT treatment when used for the treatment of conditions other than for ICI- induced GI toxicities (e.g., Infliximab is used in the treatment of Crohn's disease, rheumatoid arthritis, plaque psoriasis, and Vedolizumab is used in treating ulcerative colitis)
  6. No concern for active concomitant GI infection at the time of initiation of protocol therapy as confirmed by stool tests or as per the treating physician based on clinical presentation
  7. Patient has been cleared for enrollment by Infectious Diseases consultant or treating physician if positive infection workup or screening tests (e.g., lifelong positive T-spot due to BCG inoculation, chronic colonization) prior to initiation of protocol therapy and/ or imaging (e.g. CXR, CT CAP etc) confirms the absence of active infections (e.g. TB) within 60 days prior to initiation of protocol therapy
  8. Ability to understand and willingness to sign an form
  9. > 6 months

Exclusion criteria

Exclusion Criteria

  1. Age younger than 18 years
  2. Participants with persistent GI infection confirmed with positive stool test(s) despite completing 5 days of antibiotics prior to initiation of protocol therapy
  3. History of inflammatory bowel disease, and/or radiation enteritis or colitis with active disease status at the time of study treatment initiation
  4. Pregnant and breastfeeding women
  5. Women who have positive urine or serum pregnancy test or refuse to do pregnancy test unless last menstrual cycle was > 1 year prior to consent and/ or clear documentation states that participant is peri- or or there has been recent supporting objective evidence of 'no pregnancy' status (e.g. blood or imaging) within 30 days prior to date of study treatment
  6. treatment at onset of ICPI-induced diarrhea/colitis
  7. Any medical conditions (e.g. severe heart failure, brain hemorrhage, septic shock, etc.) that are high risk for colonoscopy procedure by the assessment of the study PI or Co-PIs.
  8. Participants who develop concurrent non-GI toxicity at the time of study treatment
  9. Donors at risk for monkeypox infection and/ or exposure as determined by a questionnaire
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Treatment (loperamide, colonoscopy, FMT)

    Patients receive loperamide PO. After 4 hours, patients undergo FMT via colonoscopy over 15-30 minutes.

    Procedure: Fecal Microbiota Transplantation · Drug: Loperamide

Interventions

  • ProcedureFecal Microbiota Transplantation

    Undergo FMT via colonoscopy

    Also known as: Fecal Material Transplantation, Fecal Transplantation, FMT, Poo Transplant, Poop Transplant, Stool Transplant

  • Given PO

06

What researchers measure

Primary outcomes

  1. Incidence of fecal microbiota transplantation (FMT)-related adverse events

    Assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5. All events are recorded with grade and attribution to FMT.

    Time frame: Up to 3 months post-FMT

  2. Clinical response/remission of immune-related diarrhea/colitis

    Clinical remission of immune related events defined as improvement of symptoms of grade 1 or lower within 2 weeks post-FMT. Clinical partial response of immune related diarrhea/colitis defined as improvement of diarrhea/colitis to a lower grade than the initial presentation but not meeting criteria of clinical remission at 2 week post-FMT time point.

    Time frame: At 2 weeks post-FMT

Secondary outcomes

  1. Recurrent immune-related diarrhea/colitis within 3 months post-FMT after initially achieving clinical remission/response

    Recurrent immune-related diarrhea colitis events occurring post-FMT are recorded throughout the follow-up period.

    Time frame: Up to 3 months post-FMT

Other outcomes

  1. Endoscopic remission (Mayo Clinic sub-score 0-1) of immune-related diarrhea/colitis

    Endoscopic remission is defined as Mayo Clinic endoscopic subscore 0 or 1 (absence of ulcers, with or without mild erythema, friability and decreased vascular pattern).

    Time frame: At 4 weeks and 8 weeks post-FMT

  2. Histological remission (resolution of active inflammation) of immune-related diarrhea/colitis

    Histological remission is defined resolution of active inflammation on biopsy sample.

    Time frame: At 8 weeks post-FMT

  3. Recurrent immune-related diarrhea/colitis following FMT and immune checkpoint inhibitors (ICPI) resumption within 6 months of ICPI resumption

    Recurrent immune-related diarrhea colitis events occurring post-FMT will be recorded throughout the follow-up period.

    Time frame: Up to 6 months after restarting ICPI

  4. Measure immunological measures (including levels of cytokines (IL-6, 17, TNF, etc.) in tissue/blood/stool samples

    Blood, stool, and colon tissues will be collected from at each scheduled time point. Markers of interest for immunological and biological profiles include levels of cytokines (IL-6, 17, TNF, etc). Special attention will focus on Bacteroidetes, Akkermansia, and Blautia.

    Time frame: Up to 3 months

  5. Frequencies of immune cells (CD4/8 T cells, regulatory T cells [Treg], macrophages, etc.) in tissue/blood/stool samples

    Blood, stool, and colon tissues will be collected from at each scheduled time point. Markers of interest for immunological and biological profiles include frequencies of immune cells (CD4/8 T cells, Treg, macrophages, etc). Special attention will focus on Bacteroidetes, Akkermansia, and Blautia.

    Time frame: Up to 3 months

07

Study locations

1 of 1 sites recruiting
  • M D Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • Yinghong Wang · Contact713-792-7672
    • Yinghong Wang · Principal investigator
08

References and documents

Publications

  • Wang Y, Fan C, Varatharajalu K, Shatila M, Cruz CC, Sun B, Lermi NO, Hayase T, Thomas A, Szymonowicz KA, Espiridion BS, Duose DY, Hayase E, Tan L, Liu Y, Chang CC, Arias CA, Junek K, DuPont HL, Jiang ZD, Kim ST, Nurieva R, Campbell MT, Tannir NM, Gao J, Watowich SS, Wang XS, Chen K, Lorenzi PL, Haymaker C, Parra ER, Jenq RR. First-line fecal microbiota transplantation for the management of immune checkpoint inhibitor-mediated diarrhea and colitis. Cell Rep Med. 2026 Sep 14:103044. doi: 10.1016/j.xcrm.2026.103044. Online ahead of print. PubMed 42735684 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04038619
Responsible party
Sponsor
First posted
Jul 31, 2019
Start date
Feb 1, 2021
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 18, 2026

Study contacts

Yinghong Wang
Contact
ywang59@mdanderson.org
281-221-9138
Yinghong Wang
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Loperamide

Start the discussion